Clinical Trial Update: Combination of Rituximab and NK Immunotherapy for B Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluating the combination of Rituximab with NK cell immunotherapy for recurrent B-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• NK immunotherapy (natural killer cell-based immunotherapy)
• Rituximab (rituximab)

Snippet

Sponsor: Fuda Cancer Hospital, Guangzhou | Conditions: B-cell Lymphoma Recurrent | Phase 1, Phase 2 | Status: COMPLETED